Global Proliferative Vitreoretinopathy Drugs and Companies Pipeline Review H2 2016

PUNE, INDIA, September 19, 2016 /EINPresswire.com/ -- The report provides comprehensive information on the therapeutics under development for Proliferative Vitreoretinopathy (PVR), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Proliferative Vitreoretinopathy (PVR) and features dormant and discontinued projects.
Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Complete Report @ https://www.wiseguyreports.com/reports/643475-proliferative-vitreoretinopathy-pvr-pipeline-review-h2-2016

Scope
- The report provides a snapshot of the global therapeutic landscape of Proliferative Vitreoretinopathy (PVR)
- The report reviews pipeline therapeutics for Proliferative Vitreoretinopathy (PVR) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Proliferative Vitreoretinopathy (PVR) therapeutics and enlists all their major and minor projects
- The report assesses Proliferative Vitreoretinopathy (PVR) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Proliferative Vitreoretinopathy (PVR)

Get Sample Report @ https://www.wiseguyreports.com/sample-request/643475-proliferative-vitreoretinopathy-pvr-pipeline-review-h2-2016

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Proliferative Vitreoretinopathy (PVR)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Proliferative Vitreoretinopathy (PVR) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Have any query @ https://www.wiseguyreports.com/enquiry/643475-proliferative-vitreoretinopathy-pvr-pipeline-review-h2-2016

Table of Content
Proliferative Vitreoretinopathy (PVR) Overview 6
Therapeutics Development 7
Pipeline Products for Proliferative Vitreoretinopathy (PVR) - Overview 7
Pipeline Products for Proliferative Vitreoretinopathy (PVR) - Comparative Analysis 8
Proliferative Vitreoretinopathy (PVR) - Therapeutics under Development by Companies 9
Proliferative Vitreoretinopathy (PVR) - Therapeutics under Investigation by Universities/Institutes 10
Proliferative Vitreoretinopathy (PVR) - Pipeline Products Glance 11
Early Stage Products 11
Proliferative Vitreoretinopathy (PVR) - Products under Development by Companies 12
Proliferative Vitreoretinopathy (PVR) - Products under Investigation by Universities/Institutes 13
Proliferative Vitreoretinopathy (PVR) - Companies Involved in Therapeutics Development 14
Novartis AG 14
Promedior, Inc. 15
RXi Pharmaceuticals Corporation 16
Proliferative Vitreoretinopathy (PVR) - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 23
Drug Profiles 25
Antisense RNAi Oligonucleotide to Inhibit CTGF for PVR - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
Drug to Inhibit TAK1 for Proliferative Vitreoretinopathy - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
LD-224 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
PRM-167 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
Small Molecules to Target Hdm2 for Proliferative Vitreoretinopathy - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
XOMA-089 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Proliferative Vitreoretinopathy (PVR) - Dormant Projects 32
Proliferative Vitreoretinopathy (PVR) - Product Development Milestones 33
Featured News & Press Releases 33
Apr 27, 2015: RXi Pharmaceuticals Announces Upcoming Presentations at Leading Partnering and Scientific Conferences 33
May 22, 2014: RXi Pharmaceuticals Granted US Notice of Allowance Covering Self-Delivering (sd-rxRNA) Technology Platform 34
May 07, 2012: Promedior Presents Preclinical Data Of Pentraxin-2 At ARVO Annual Meeting 35
May 01, 2012: Promedior To Present Preclinical Data Of Pentraxin-2 At ARVO Annual Meeting 36
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37

Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=643475
Continued…

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here